Older weight-loss medications achieve approximately five percent reduction in body weight over placebo, whereas these new GLP-1 agonists, like Ozempic, produce about triple the effect, about 15 percent
Long-term safety data is still being collected, but current research suggests no unexpected long-term risks beyond those seen with GLP-1 and GIP medications
Those events belong to a regulated product and patient population
Dehydration and renal function : Dehydration resulting from gastrointestinal side effects requires attention, as it can affect overall health, medication levels, and potentially lead to acute kidney injury, especially in those with pre-existing renal impairment
This sudden change in signaling can manifest as cramping, especially if you consume larger meals or eat foods high in fat or fiber before your body has fully adapted